藥明生物(02269.HK)授出394.46萬股獎勵計劃受限制股份予486名僱員
格隆匯11月23日丨藥明生物(02269.HK)公佈,於2021年11月23日,已根據受限制股份獎勵計劃批准授出合共394.46萬股受限制股份(受限制股份獎勵計劃受限制股份)予集團486名僱員,股份於授出日期在聯交所所報的收市價為每股股份101.30港元。
此外,已根據全球合夥人股份獎勵計劃批准授出合共272.4萬股受限制股份(全球合夥人計劃受限制股份)予集團198名僱員,受限制股份佔公司於本公吿日期已發行股本約0.06%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.